Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O3CX
|
|||
| Former ID |
DNCL002313
|
|||
| Drug Name |
BMS-906024
|
|||
| Synonyms |
1401066-79-2; UNII-DRL23N424R; BMS 906024; DRL23N424R; (2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide; SCHEMBL12543868; DTXSID30161234; CHEBI:131164; ZINC100285156; SB16893; DB12006; KB-145938; Z-3229; BMS-906024, > Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
| Lymphoma [ICD-11: 2A80-2A86] | Phase 1 | [2] | ||
| T-cell acute lymphocytic leukaemia [ICD-11: 2B33.4] | Phase 1 | [2] | ||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H26F6N4O3
|
|||
| Canonical SMILES |
CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)C(CCC(F)(F)F)C(CCC(F)(F)F)C(=O)N)C3=CC=CC=C3
|
|||
| InChI |
1S/C26H26F6N4O3/c1-36-19-10-6-5-9-18(19)20(15-7-3-2-4-8-15)34-22(24(36)39)35-23(38)17(12-14-26(30,31)32)16(21(33)37)11-13-25(27,28)29/h2-10,16-17,22H,11-14H2,1H3,(H2,33,37)(H,35,38)/t16-,17+,22+/m0/s1
|
|||
| InChIKey |
AYOUDDAETNMCBW-GSHUGGBRSA-N
|
|||
| CAS Number |
CAS 1401066-79-2
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:131164
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03691207) A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01292655) Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.